Rapid Sequence Intubation With Rocuronium-Sugammadex Compared With Succinylcholine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00953550|
Recruitment Status : Completed
First Posted : August 6, 2009
Last Update Posted : March 2, 2011
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Rapid sequence intubation is used, when there is an elevated risk of aspiration to the lungs of stomach content. It is typically used in acute settings that require acute surgery or in prehospital settings, but also in specific risk patients requiring elective surgery. The reason for conducting rapid sequence intubation is to minimize the risk of pulmonary aspiration and at the same time achieve a fast induction of anaesthesia and intubation. Rapid sequence intubation is a procedure with a high risk of complications in itself. The time period from induction of anaesthesia to intubation is particularly risky, because the patient is apneic. This study addresses this problem by investigating, how quickly spontaneous respiration can be reestablished after a rapid sequence intubation when using Rocuronium-Sugammadex compared to Succinylcholine. This is a pilot protocol that is intended to establish a sample size for the full protocol.
Study hypothesis: The time from correct tube placement to spontaneous respiration is shorter when using Rocuronium/Sugammadex compared to Succinylcholine.
|Condition or disease||Intervention/treatment||Phase|
|Rapid Sequence Intubation||Drug: Rocuronium-Sugammadex Drug: Succinylcholine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||61 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||Rapid Sequence Intubation With Rocuronium-Sugammadex Compared With Succinylcholine|
|Study Start Date :||September 2009|
|Actual Primary Completion Date :||January 2011|
|Actual Study Completion Date :||February 2011|
Rocuronium 1,0 mg/kg is administered iv initially. Upon intubation Sugammadex is administered 16 mg/kg iv.
|Active Comparator: Succinylcholine||
- Time from verified correct tube placement after intubation to spontaneous respiration, defined as respiration frequency of >8/minute, tidal volume >3ml/kg and a saturation of >90% for 30 seconds. [ Time Frame: 20 minutes ]
- Duration of action. Measured as the time from administration of the neuromuscular blocking agent to the T1-value in Train-of-Four (TOF) returns to >90% of T1-max. [ Time Frame: 20 minutes ]
- Intubation Difficulty Scale (IDS) [ Time Frame: 20 minutes ]
- Intubation conditions [ Time Frame: 20 minutes ]
- Side effect - Muscle ache. [ Time Frame: Postoperative (within 24 hours) ]
- Side effect - Tachycardia (>100 beats per minute). [ Time Frame: 20 minutes ]
- Side effect - Bradycardia (<50 beats per minute). [ Time Frame: 20 minutes ]
- Side effect - Awareness/recall. Evaluated by modified Brice Questionaire. [ Time Frame: Postoperative (within 24 hours) ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 60 Years (Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Elective surgical patients with a planned rapid sequence induction of anaesthesia.
- Informed consent.
- Legally competent.
- Be able to understand Danish and be able to read the given information in Danish.
- Females can only participate if they have reached menopause, have had hysterectomy performed, use a coil as birthcontrol, or if they are sterilized.
- Presence of kidney disease, defined as S-creatinine >0,200 mmol/L.
- Known lung or heart disease, defined as NYHA-class >2 or CCS-class >2.
- Known allergic reactions to Rocuronium, Suxamethon, Propofol or Sugammadex.
- Contraindications to Suxamethon. Including raised P-potassium (>5,0 mmol/L), untreated glaucoma, neuromuscular disorders or disposition to malignant hyperthermia.
- Body mass index of >35 kg/m2.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00953550
|Copenhagen, Denmark, 2100|
|Herlev, Denmark, 2730|
|Principal Investigator:||Martin K Sørensen, MD||Rigshospitalet, Denmark|
|Responsible Party:||Lars Rasmussen, Department of Anesthesia, Center of Head and Orthopedics, Copenhagen University Hospital Rigshospitalet|
|Other Study ID Numbers:||
|First Posted:||August 6, 2009 Key Record Dates|
|Last Update Posted:||March 2, 2011|
|Last Verified:||December 2010|
Neuromuscular Nondepolarizing Agents
Neuromuscular Blocking Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Neuromuscular Depolarizing Agents